Marinomed Biotech AG Completes Restructuring Proceedings

Marinomed Biotech AG has successfully concluded its restructuring proceedings, as confirmed by the Korneuburg regional court. The process, initiated in August 2024, required achieving key milestones, including unanimous creditor approval of the restructuring plan and securing necessary funds. With these criteria met, the Management Board regains control from the insolvency administrator.

The restructuring plan includes a 30% creditor quota, payable over two years. A crucial element is the sale of the Carragelose business to Unither Pharmaceuticals, with shareholder consent obtained during a December meeting. CEO Andreas Grassauer emphasizes the need to develop new strategies while advancing Marinosolv and Solv4U commercialization.